Medications for Black people
Certain medications may be less effective or carry higher risks for Black patients due to genetic variations (pharmacogenomics) affecting drug metabolism or physiological differences, particularly in treating hypertension, heart failure, and asthma. Common examples include reduced effectiveness of ACE inhibitors for hypertension, increased risk of angioedema with ACE inhibitors, and lower response rates to albuterol for asthma. Wallace House Center for Journalists +3 Medications with Varied Effectiveness or Risks - ACE Inhibitors (e.g., Lisinopril, Ramipril): Often less effective as a first-line treatment for high blood pressure in Black patients, who may respond better to calcium channel blockers or diuretics. They also pose a higher risk of angioedema (swelling). - Beta-Blockers: Some studies suggest they may not be as effective for heart failure in African Americans. - Albuterol: Often less effective for asthma in African American and Puerto Rican patients compared to other groups, leading to higher rates of treatment failure. - Warfarin (Coumadin): African Americans may require different dosing strategies due to genetic variations in metabolism. - Antiarrhythmic drugs: Potential, though complex, issues with effectiveness and adverse effects. Important Context - Individualized Care: While research identifies trends, treatment should be personalized based on individual genetics, lifestyle, and health conditions, rather than blanket assumptions based on race. - Social Factors: Differences in drug response are often attributed to environmental factors, such as stress, diet, and access to healthcare, rather than strictly genetics. - Research Limitations: Many pharmaceutical trials have historically lacked diversity, which can impact how medications are initially approved and recommended.